Abstracts

579 – Macrophage Training Reactivates Latent HIV-1 From HAART-Suppressed PBMCs of PLWH

Background HIV virus persists in a latent but activatable chronic state, predominantly through epigenetic modification of resting CD4+ T-cells and other immune cells such as macrophages. This necessitates lifelong combination antiretroviral therapy (cART) for people living with HIV (PLWH). Trained immunity is a myeloid specific phenomenon where chromatin is relaxed to a less condensed state…

507 – Temsavir Treatment Improves Recognition of HIV-1 Infected Cells by Broadly Neutralizing Antibodies

Background HIV-1 envelope glycoprotein (Env) is expressed on the surface of infected cells, making it an attractive target for the clearance of these cells through antibody-mediated immune activities, such as antibody-dependent cellular cytotoxicity (ADCC). It was previously demonstrated that treatment with temsavir (TMR), a small molecule, can enhance the binding of the broadly neutralizing antibody…

516 – Anatomical Sites in FIND 2.0 Decedents Harbor Compartmentalized, Transcriptionally Intact HIV-1 Env

Background HIV-1 persistence poses a significant barrier to HIV eradication. Findings from the largest post-mortem study (FIND 2.0), which utilized minimally invasive tissue sampling in 38 virally suppressed individuals on antiretroviral therapy (ART) (VS; <400 copies/mL) and 22 unsuppressed (VU) untreated individuals showed the presence of proviral DNA in all 11 anatomically distinct compartments. We report detailed genotypic…

498 – Anti-IL-10/Anti-PD-1 Dual Blockade Leads to IFN-Related HIV Elite Control Signatures

Background Elimination of latently HIV-infected cells remain the biggest challenge to reach a cure. Current immunotherapy approaches have focused on targeting the adaptive arm of the immune system, such as therapeutic vaccines and the passive transfer of broadly neutralizing antibodies. Recent studies showed that epigenetic reprogramming of innate myeloid cells triggered by adjuvants promoted protective…

582 – Predominance of Non-T Follicular Helper Cell Subsets in the Lymph Node Viral Reservoir During ART

Background HIV-1 cure strategies require a comprehensive understanding of cellular phenotype of HIV tissue reservoirs for effective and selective targeting. While recent data have demonstrated the highly heterogeneous nature of peripheral blood CD4+ T cells subsets comprising the HIV reservoir of antiretroviral therapy (ART) treated people with HIV (PWH), CD4+ T follicular helper (Tfh) cells…

557 – The Paucity of Clonal SIV Proviral Sequences During Early ART Treatment

Background The persistent HIV-1 reservoir is comprised of individual proviral clones with a corresponding integration site. The proviral landscape in the blood of long-term ART-suppressed persons with HIV-1(PWH)  is often dominated by identical sequences, signifying antigen-driven proliferation. The clonal structure of the SIV reservoir during ART suppression is less well-characterized, particularly in the first 2 years…

509 – Myeloid Targeted and Enhanced Endosomal Escapable LNPs Improve Latent HIV-1 Elimination Efficacy

Background A cure for HIV remains elusive as the excision of latent proviral DNA by adenovirus-based therapeutic systems has failed to date due to vector immunogenicity and limited targeting to viral reservoirs. In contrast, lipid nanoparticles (LNPs) are promising for targeting viral reservoirs, offering greater cargo-carrying capacity and reduced immune responses. However, limitations in endosomal…